Testosterone transdermal - Transdermal Delivery Solutions

Drug Profile

Testosterone transdermal - Transdermal Delivery Solutions

Alternative Names: Testagen HypoSpray; Testagen TDS; Testosterone spray -Transdermal Delivery Solutions

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transdermal Delivery Solutions Corp
  • Developer St. Bartholomews Hospital; Transdermal Delivery Solutions Corp
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypogonadism

Most Recent Events

  • 19 Apr 2016 Waiting for QC - MHRA approves CTAs for transdermal testosterone to begin phase III trials in hypogonadism
  • 01 Apr 2016 Transdermal Delivery Solutions initiates the phase II TRANSFERENCE trial for Hypogonadism in United Kingdom (NCT02733133)
  • 26 Jan 2016 Phase II development for Hypogonadism is ongoing in United Kingdom (transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top